SCHEMBL1640262

SCHEMBL1640262

CCc1nc(-c2cccc(NC(=O)c3c(F)cccc3F)c2)c(-c2ccnc(Nc3ccc(OCCN(C)C)c(F)c3)n2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.59
IGF1R P08069 12/20 0.53
EGFR P00533 5/20 0.53
ERBB2 P04626 5/20 0.53
BRAF P15056 2/20 0.53
KDR P35968 2/20 0.49
PRKD3 O94806 1/20 0.49
MAP4K4 O95819 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
CSF1R P07333 1/20 0.49
RET P07949 1/20 0.49
MET P08581 1/20 0.49
ROS1 P08922 1/20 0.49
FLT1 P17948 1/20 0.49
MAP4K2 Q12851 1/20 0.49
STK3 Q13188 1/20 0.49
ROCK1 Q13464 1/20 0.49
LRRK2 Q5S007 1/20 0.49
TAOK1 Q7L7X3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642113 0.94 SLC2A1 (0.54) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL1640704 0.92 SLC2A1 (0.58) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL1642125 0.88 BRAF (0.57) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL12766944 0.87 IGF1R (0.54) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL1641857 0.86 SLC2A1 (0.54) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL1641698 0.85 SLC2A1 (0.53) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL12766445 0.85 SLC2A1 (0.53) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL12726169 0.85 IGF1R (0.53) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL1641164 0.85 SLC2A1 (0.53) SLC2A1IGF1REGFRERBB2BRAF
SCHEMBL1641811 0.85 SLC2A1 (0.52) SLC2A1IGF1REGFRERBB2BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US claimed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 SLC2A1 2698/4885IGF1R 396/4885EGFR 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.